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Abstract
Introduction: Chronic liver disease caused by HBV and HCV infections, due to its great prevalence and serious medical consequences, is 
at the present time a significant clinical problem. An impaired liver function can provoke severe disturbances in calcium and phosphorus 
homeostasis, and consequently in the bone metabolism resulting in hepatic osteodystrophy. The aim of this study was to determine whether 
there are significant differences in bone mineral density (BMD) and/or circadian levels of hormones connected with bone metabolism and 
bone turnover markers in patients with chronic viral hepatitis.
Material and methods: Circadian levels (AUC, area under the curve) of GH, IGF-I, IGFBP-3, osteocalcin (BGLAP), C-terminal telopeptide 
of type I collagen (ICTP), PTH, 25(OH)D, total calcium and total phosporus were measured in the blood of members of the study group 
(n = 80). BMD was assessed using the dual-energy X-ray absorptiometry method of the L2-L4 lumbar spine. Data was compared to that 
of healthy individuals (n = 40).
Results: BMD (1.05 g/cm3 vs. 1.20 g/cm3), total calcium concentration (2.20 mmol/L vs. 2.45 mmol/L), total phosphorus concentration 
(1.06 mmol/L vs. 1.33 mmol/L), IGF-I (AUC 3,982.32 ng/mL vs. 5,167.61 ng/mL), IGFBP-3 (AUC 725.09 ng/L vs. 944.35 ng/L), 25(OH)D 
(AUC 356.35 ng/mL vs. 767.53 ng/mL) and BGLAP (AUC 161.39 ng/L vs. 298 ng/L) were lower in the study group. GH (AUC 88.3 ng/mL 
vs. 48.04 ng/mL), iPTH (AUC 1,201.94 pg/mL vs. 711.73 pg/mL) and ICTP (AUC 104.30 µg/L vs. 54.49 µg/L) were higher in patients with 
hepatitis. Positive correlations were noted between bone mineral density and IGF-I, IGFBP-3, and BGLAP levels.
Conclusions: Chronic viral hepatitis causes a decrease in bone mineral density. Impaired liver function disrupts homeostasis of the cal-
cium–vitamin D–parathyroid hormone axis and provokes secondary hyperparathyroidism. Chronic viral hepatitis induces a decrease 
in the synthesis of IGF-I and IGFBP-3 and an increase in GH secretion. Hepatic osteodystrophy is probably caused by both changes in 
calciotropic hormones as well as in the somatotropin hormone axis.  (Endokrynol Pol 2015; 66 (1): 22–29)
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Streszczenie
Wstęp: Przewlekłe zakażenia HBV i HCV są obecnie znaczącym problemem klinicznym. W wyniku zaburzeń czynności wątroby może 
dochodzić do zaburzeń w homeostazie wapnia i fosforu oraz w metabolizmie kostnym prowadzących do osteodystrofii wątrobowej. 
Celem badania była ocena gęstości mineralnej kości (BMD), okołodobowych stężeń hormonów związanych z metabolizmem kości oraz 
markerów obrotu kostnego u chorych na przewlekłe wirusowe zapalenie wątroby.
Materiał i metody: W grupie badanej (n = 80) oznaczano we krwi okołodobowe stężenia (AUC, area under the curve [pole pod krzywą]) 
GH, IGF-I, IGFBP-3, osteokalcyny (BGLAP), C-terminalnego telopeptydu kolagenu typu I (ICTP), PTH, 25(OH)D, całkowitego wapnia 
oraz fosforu. BMD (L2-L4) oceniono z użyciem DEXA. Dane porównano ze zdrową grupą kontrolną (n = 40).
Wyniki: BMD (1,05 g/cm3 vs. 1,20 g/cm3), stężenia wapnia (2,20 mmol/l vs. 2,45 mmol/l) i fosforu (1,06 mmol/l vs. 1,33 mmol/l), IGF-I (AUC 
3982,32 ng/ml vs. 5167,61 ng/ml), IGFBP-3 (AUC 725,09 ng/l vs. 944,35 ng/l), 25(OH)D (AUC 356,35 ng/ml vs. 767,53 ng/ml), BGLAP (AUC 
161,39 ng/l vs. 298 ng/l) okazały się niższe w grupie badanej niż w grupie kontrolnej, zaś stężenia GH (AUC 88,3 ng/ml vs. 48,04 ng/ml), 
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hormone (PTH) and calcidiol [25(OH)D] reflecting the 
level of vitamin D. Of bone turnover markers, we chose 
osteocalcin (BGLAP; bone gamma-carboxyglutamate 
protein) as an indicator of osteogenesis, and C-terminal 
telopeptide of type I collagen (ICTP) as an indicator of 
bone loss.
Material and methods 
Eighty patients with chronic viral hepatitis (B or/and C) 
were included in the study. The study group consisted 
of 45 men with a mean age of 37 years (SD = 6.3 years) 
and 35 women with a mean age of 34 years (SD = 5.2 
years). The inclusion criterion was a diagnosis of chronic 
B or C hepatitis. This diagnosis had been based on the 
clinical picture, laboratory tests results — ALT, AST, 
GGTP, alkaline phosphatase, total bilirubin, INR, pro-
teinogram, serological tests results — HBsAg, HBcAg, 
HBeAg, anti-HBs, anti-HBc, anti-HBe, molecular tests 
results — in B-type hepatitis the presence of HBV 
DNA and DNA-polymerase activity, in C-type hepatitis 
the presence of HCV RNA and liver biopsy. Hepatitis 
group candidates were excluded if they suffered from 
chronic diseases of the endocrine system, cardiovas-
cular system, respiratory system, or excretory system. 
Also candidates who used calcium supplements, vita-
min D, corticosteroids or other drugs influencing bone 
metabolism were excluded. Additional exclusion criteria 
were a history of alcohol abuse or a family history of 
osteoporosis. The control group consisted of 40 healthy 
volunteers. This group included 20 men and 20 women 
with a mean age of 36 years (SD = 6.7 years) who did 
not meet exclusion criteria. All participants underwent 
a full clinical examination including calculation of BMI 
and routine biochemical blood tests. Permission to 
conduct the study was obtained from the Local Eth-
ics Committee for Scientific Research of the Medical 
University of Silesia.
Blood sample analyses
All participants had a peripheral venous catheter es-
tablished into their antecubital vein one hour before 
the start of the study. Blood samples, in the amount of 
8 ml each, were collected through this catheter at 08.00, 
12.00, 16.00, 20.00, 24.00 and 04.00. The samples were 
centrifuged to obtain blood serum, which was frozen 
PTH (AUC 1201,94 pg/ml vs. 711,73 pg/ml) i ICTP (AUC 104,30 µg/l vs. 54,49 µg/l) były większe u osób z zapaleniem wątroby. Stwierdzono 
dodatnią korelację między BMD a stężeniami IGF-I, IGFBP-3 oraz BGLAP. 
Wnioski: Przewlekłe wirusowe zapalenie wątroby prowadzi do zmniejszenia gęstości mineralnej kości. Upośledzona funkcja wątroby 
zakłóca homeostazę wapnia, witaminy D, PTH, prowadzi do wtórnej nadczynności przytarczyc. Dochodzi do zmniejszenia syntezy IGF-I 
i IGFBP-3 oraz do zwiększenia wydzielania GH. Osteodystrofia wątrobowa jest prawdopodobnie spowodowana zarówno poprzez zmiany 
stężenia hormonów kalciotropowych, jak i zaburzenia funkcjonowania osi somatotropinowej.  (Endokrynol Pol 2015; 66 (1): 23–29)
Słowa kluczowe: GH; IGF-I; osteokalcyna; witamina D; gęstość mineralna kości; przewlekłe zapalenie wątroby
Introduction
Chronic liver disease caused by HBV and HCV infec-
tions is at the present time a significant clinical problem, 
given the numerous complications of liver dysfunc-
tion as a consequence of a chronic inflammatory state. 
Moreover, the prevalence of HBV and HCV infections 
is estimated at respectively 0.1-7% and 0.4-20% of the 
general population in some European regions [1].
The liver, due to its complex metabolic and secre-
tory functions, has long been classified as a functional 
part of the endocrine system [2–5]. Among the many 
aspects of the interaction with the endocrine system, 
an interesting one is the effect on bone metabolism. 
This influence is manifested by the interaction with the 
somatotropic axis, the regulation of the calciotropic hor-
mones — PTH and vitamin D, or even bone turnover 
markers such as osteocalcin, or C-terminal telopeptide 
of type I collagen [6–10].
According to previous studies, osteopenia, osteopo-
rosis or osteomalacia may affect as many as 40–50% of 
patients suffering from impaired liver function. These 
changes appear in the literature under the name of 
hepatic osteodystrophy [11–14]. Primary osteoporosis is 
characterised by specific features: it applies to younger 
patients, requires a primary disease, and appears as the 
result of a combination of different pathogenetic factors 
[15–17]. To date, the pathogenesis and mechanism of 
hepatic osteodystrophy has not been well explored. It 
is still not possible to consistently and unambiguously 
present the factors contributing to this phenomenon 
[5, 11–13, 18–21].
The aim of this study was to evaluate some potential 
pathogenetic factors influencing bone status in patients 
with chronic active viral hepatitis, and to determine 
their importance in hepatic osteodystrophy develop-
ment. For this purpose, we decided to assess the bone 
mineral density (BMD) and hormones and markers 
associated with bone metabolism. In evaluating these 
parameters we took into account the existence of 
diurnal chronobiological cycles, by making multiple 
measurements throughout the day. Among the cho-
sen parameters were: somatotropic axis hormones 
— growth hormone (GH), insulin-like growth factor-I 
(IGF-I), insulin-like growth factor binding protein 3 
(IGFBP-3), and calciotropic hormones — parathyroid 
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at –70°C for subsequent analysis. In every serum sam-
ple, the radioimmunological assay method was used 
to assess the concentration of selected parameters: 
Growth hormone (GH-RIA kit, OPiD POLATOM, 
Poland), insulin-like growth factor-I (IGF-I RIA-kit, 
Biosource, Belgium), insulin-like growth factor bind-
ing protein-3 (IGFBP-3 IRMA-kit, Diagnostic Systems 
Laboratories, TX, USA), osteocalcin (BGLAP IRMA-kit, 
Biosource, Belgium), C-terminal telopeptide of type I 
collagen (ICTP RIA-kit, Orion Diagnostica, Finland), 
parathyroid hormone (iPTH IRMA-kit, Biosource, 
Belgium), and calcidiol (25(OH)D3 IRMA-kit, Bio-
source, Belgium).Total calcium serum concentration 
was assessed by the colorimetric method (Calcium 
Liquicolor, Humen, Germany), as was total inorganic 
phosphorus concentration (Phosphorous Liquirapid, 
Humen, Germany).
Bone densitometry
All participants underwent assessment of bone mineral 
density (BMD) with the use of the dual-energy X-ray 
absorptiometry method (DEXA) of the L2-L4 lumbar 
spine. A Lunar DPX densitometer (General Electric, 
USA) was used to make measurements. Measurement 
results were presented as either absolute density values 
[g/cm3] or T-score and Z-score values.
Statistics
All acquired data was implemented to create a database 
using Microsoft Excel forming a part of Microsoft Office 
2000 (Microsoft, USA). For each quantitative parameter, 
basic statistical characteristics were made — mean, 
median, standard deviation (SD), and standard error 
of the mean (SEM). Area under curve (AUC) values 
of the parameters was determined by the trapezoidal 
method. Shapiro-Wilk test was performed for the 
evaluation of a normal distribution parameter. Stu-
dent’s t-test was used for the comparison of unpaired 
groups of parameters that follow normal distribution. 
In the use of unrelated variables, Fisher’s exact test was 
used to check the homogeneity of variance. Pearson’s 
correlation coefficient was used to investigate multi-
variate data correlation. A p value < 0.05 was accepted 
as statistically significant. 
Results
We found a significant difference in the ALT serum 
concentration. It was greatly elevated (120.3 IU/L vs. 
19.2 IU/L, p < 0.001) in patients compared to controls 
(Table I and II).
We observed a difference in BMD in the L2-L4 
vertebrae densitometry (DEXA) between study 
participants and the control group, taking into ac-
count both the absolute BMD values (1.05 g/cm3 
vs. 1.20 g/cm3, p = 0.0011) and the indications of 
Z-score (–0.36 vs. 0.48, p < 0.05) and T-score (–0.52 
vs. 0.18, p < 0.05). We noted, however, that despite 
much lower values compared to the controls, the 
results of the study group members were within 
the reference values. In the group of patients with 
chronic hepatitis, we found in blood lower total cal-
cium levels (2.20 mmol/L vs. 2.45 mmol/L, p < 0.001) 
and inorganic phosphorus levels (1.06 mmol/L vs. 
1.33 mmol/L, p < 0.001) (Table III).
We observed significantly increased total daily re-
lease of GH in the study group compared to controls 
(88.3 ng/mL vs. 48.04 ng/mL, p < 0.001). However, we 
Table I. Characteristics of patients with chronic viral 
hepatitis and control group
Tabela I. Charakterystyka chorych z przewlekłym wirusowym 
zapaleniem wątroby oraz grupy kontrolnej 
Chronic hepatitis 
(N = 80)
Control group 
(N = 40)
p value
Age [years] 34 (SD ± 0.82) 36 (SD ± 1.50) NS
BMI [kg/m2] 22.3 (SD ± 0.50) 22.8 (SD ± 0.89) NS
ALT [IU/L] 120.3 (SD ± 12.74) 19.2 (SD ± 1.65) P < 0.001
ALP [IU/L] 180.43 (SD ± 7.51) 182.30 (SD ± 7.02) NS
Total bilirubin 
[µmol/L]
19.4 (SD ± 2.57) 13.2 (SD ± 1.58) NS
Creatinine 
[µmol/L]
89.6 (SD ± 3.38) 84.7 (SD ± 3.89) NS
BMI — body mass index; ALT — alanine transaminase; ALP — alkaline 
phosphatase; NS — statistically non-significant
Table II. Bone mineral density, total calcium and inorganic 
phosphorus parameters of patients with chronic hepatitis 
and control group
Tabela II. Gęstość mineralna kości, stężenie wapnia oraz 
fosforu we krwi u chorych z przewlekłym wirusowym 
zapaleniem wątroby oraz w grupie kontrolnej
Chronic hepatitis Control s p value
BMD [g/cm3] 1.05  
(SD ± 0.029)
1.20  
(SD ± 0.032)
p = 0.0011
BMD Z-score –0.36 0.48 p < 0.05
BMD T-score –0.52 0.18 p < 0.05
Total calcium 
[mmol/L]
2.20  
(SD ± 0.031)
2.45  
(SD ± 0.054)
p < 0.001
Inorganic phosphorus 
[mmol/L]
1.06  
(SD ± 0.029)
1.33  
(SD ± 0.036)
p < 0.001
BMD — bone mineral density
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did not notice significant changes in the daily oscillation 
profile of GH ejection. The study group was characterised 
by lower daily concentrations of IGF-I (3,982.32 ng/mL 
vs. 5,167.61 ng/mL, p < 0.001) compared to controls. 
IGFBP-3 showed similar changes (725.09 ng/L vs. 
944.35 ng/L, p < 0.001). We did not observe changes 
in the daily oscillations of these parameters (Table IV).
Daily secretion of calcidiol was lower in patients 
with chronic viral hepatitis compared to control group 
(356.35 ng/mL vs. 767.53 ng/mL, p < 0.001). Moreover, 
we noted a flattening of the profile of daily 25(OH)D 
oscillation in patients with hepatitis, manifested as the 
disappearance of the peak of the highest concentra-
tion which occurred about 12.00 in the healthy control 
group. An inverse relationship concerned the diurnal 
concentration of intact parathyroid hormone (iPTH), 
which was higher in the study group (1,201.94 pg/mL 
vs. 711.73 pg/mL, p < 0.001) (Table V).
We observed that the daily concentration of osteo-
calcin was lower in patients with hepatitis than in the 
control group (161.39 ng/L vs. 298.00 ng/L, p < 0.001). 
In the case of ICTP, we noticed an increase in its release 
among participants of the study group (104.30 µg/L vs. 
54.49 µg/L, p < 0.001).
Our results revealed a statistically significant posi-
tive correlation between BMD values and diurnal serum 
concentrations of IGF-I, IGFBP-3 and BGLAP in blood. 
In addition, we found a positive link between the con-
centrations of IGFBP-3 and BGLAP. We also observed 
a significant negative bond between BMD values 
and the daily GH secretion. Additionally, we found 
a negative correlation linking the daily levels of IGF-I 
and ICTP or between IGF-I and iPTH. 
Discussion
The material analysed in this paper is highly homo-
geneous. Among the participants of the study group, 
we did not identify the features of cirrhosis of the 
liver, severe cholestasis, or other conditions that may 
have an impact on the calcium-phosphate metabolism. 
The general characteristics differentiating feature 
of research subjects for the members of the control 
group was a significantly elevated level of alanine ami-
notransferase (ALT; 120.3 IU/L vs. 19.2 IU/L, p < 0.001), 
reflecting active inflammation of the liver. Moreover, 
individuals included in our study were characterised 
by a relatively low age (mean age 34 years, SD = 5.2 
years), which enabled us to exclude changes in bone 
metabolism associated with senility [3, 14, 21–26]. In our 
study, we implemented repeated measurements over 
the course of 24 hours, allowing us to reflect diurnal 
level variations with respect to chronobiological cycles 
[3, 4, 8, 27–29].
In our study, we found a statistically significant 
difference in BMD expressed either as absolute values, 
or as a T-score and Z-score occurring between patients 
with hepatitis and the controls (BMD vs. 1.05 g/cm3. 
1.20 g/cm3; p = 0.0011, T-score –0.52 vs. 0.18, p < 0.05, 
Z-score –0.36 vs. 0.48, p < 0.05). The results, despite 
Table III. Diurnal oscillations of GH, IGF-I and IGFIBP-3 concentrations in blood of patients with chronic viral hepatitis 
and control group
Tabela III. Okołodobowe stężenia GH, IGF-I, IGFBP-3 we krwi chorych z przewlekłym wirusowym zapaleniem wątroby oraz 
w grupie kontrolnej
Sampling 
time
GH [ng/mL] IGF-I [ng/mL] IGFBP-3 [ng/L]
Study  
group
Control  
group
p value Study  
group
Control  
group
p value Study  
group
Control  
group
p value
08.00 2.70 
(SD ± 0.073)
1.21 
(SD ± 0.034)
p < 0.001 183.93 
(SD ± 8.29)
263.03 
(SD ± 9.25)
p < 0.001 39.97 
(SD ± 1.27)
50.16 
(SD ± 2.37)
p < 0.001
12.00 3.51 
(SD ± 0.071)
1.23 
(SD ± 0.034)
p < 0.001 181.24 
(SD ± 6.45)
251.07 
(SD ± 9.59)
p < 0.001 38.62 
(SD ± 1.19)
48.39 
(SD ± 1.87)
p < 0.001
16.00 3.92 
(SD ± 0.092)
2.52 
(SD ± 0.123)
p < 0.001 206.55 
(SD ± 7.72)
252.94 
(SD ± 8.62)
p < 0.001 38.34 
(SD ± 1.44)
46.70 
(SD ± 2.41)
p = 0.0036
20.00 5.93 
(SD ± 0.193)
4.56 
(SD ± 0.119)
p < 0.001 217.49 
(SD ± 7.82)
274.87 
(SD ± 9.07)
p < 0.001 35.84 
(SD ± 1.37)
48.79 
(SD ± 2.20)
p < 0.001
24.00 6.01 
(SD ± 0.116)
3.56 
(SD ± 0.106)
p < 0.001 233.76 
(SD ± 8.03)
282.19 
(SD ± 9.29)
p < 0.001 34.13 
(SD ± 1.17)
48.29 
(SD ± 2.22)
p < 0.001
04.00 4.37 
(SD ± 0.205)
1.32 
(SD ± 0.141)
p < 0.001 181.45 
(SD ± 7,06)
240.39 
(SD ± 8.37)
p < 0.001 31.43 
(SD ± 1,32)
42.98 
(SD ± 2.39)
p < 0.001
AUC 88.30 
(SD ± 1.824)
48.04 
(SD ± 1.294)
p < 0.001 3,982.32 
(SD ± 133.012)
5,167.61 
(SD ± 162.95)
p < 0.001 725.09 
(SD ± 21.83)
944.35 
(SD ± 37.67)
p < 0.001
GH — growth hormone concentration; IGF-I — insulin-like growth factor 1; IGFBP-3 — insulin-like growth factor binding protein 3; AUC — area under curve
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a decrease in BMD values, do not meet the criteria for 
the diagnosis of osteopenia or osteoporosis [15, 16]. 
Our results comply with those of previous reports 
[30-35], but the loss of bone mass among our sub-
jects was significantly lower than has been found by 
some other authors. We believe that this is due to the 
decreased severity of hepatic impairment presented 
by our patients. Pelazas-Gonzalez et al. [36] observed 
that chronic HCV infection in well-nourished patients 
with preserved liver function does not cause osteo-
porosis. The selection of our study group, excluding 
cholestasis, helped us to eliminate the influence of 
abnormal intestinal absorption of calcium caused 
by bile obstruction [37] and cholestasis itself, which 
is considered to be an independent risk factor for 
osteoporosis [38].
Table IV. Diurnal oscillations of 25(OH)D and iPTH concentrations in blood of patients with chronic viral hepatitis and in 
control group
Tabela IV. Okołodobowe stężenia 25(OH)D i iPTH we krwi chorych z przewlekłym wirusowym zapaleniem wątroby oraz 
w grupie kontrolnej
Sampling time 25(OH)D [ng/mL] iPTH [pg/mL]
Study group Control group P value Study group Control group p value
08.00 18.35  
(SD ± 1.35)
34.90  
(SD ± 3.82)
p < 0.001 56.46  
(SD ± 8.97)
35.72  
(SD ± 6.53)
p = 0.0384
12.00 18.20  
(SD ± 1.43)
48.10 
(SD ± 6.32)
p < 0.001 53.11  
(SD ± 5.36)
33.25  
(SD ± 4.78)
p = 0.0061
16.00 17.49  
(SD ± 1.69)
37.12  
(SD ± 4.37)
p < 0.001 64.98 
(SD ± 10.71)
38.33  
(SD ± 8.09)
p = 0.0107
20.00 17,72 
(SD ± 1,60)
38.90 
(SD ± 7.13)
p = 0.0062 55.21 
(SD ± 6.68)
33.04  
(SD ± 5.06)
p = 0.0056
24.00 17.25  
(SD ± 1.39)
35.84  
(SD ± 3.86)
p < 0.001 57.05 
(SD ± 6.50)
32.12  
(SD ± 4.43)
p = 0.0013
04.00 17.85  
(SD ± 1.82)
32.38 
(SD ± 4.23)
p = 0.0055 70.44 
(SD ± 10.95)
39.38  
(SD ± 9.51)
p = 0.0033
AUC 356.35 
(SD ± 28.74)
767.53 
(SD ± 356.71)
p < 0.001 1,201.94 
(SD ± 114.62)
711.73 
(SD ± 121.68)
p < 0.001
25(OH)D — calcidiol; iPTH — intact parathyroid hormone; AUC — area under curve
Table V. Diurnal oscillations of BGLAP and ICTP concentrations in blood of patients with chronic viral hepatitis and in 
control group
Tabela V. Okołodobowe stężenia BGLAP i ICTP we krwi chorych z przewlekłym wirusowym zapaleniem wątroby oraz w grupie 
kontrolnej
Sampling time BGLAP [ng/L] ICTP [μg/L]
Study group Control group p value Study group Control group p value
08.00 8.26 
(SD ± 0.71)
13.36 
(SD ± 1.04)
p < 0.001 5.72 
(SD ± 0.46)
2.77 
(SD ± 0.29)
p < 0.001
12.00 7.58 
(SD ± 0.52)
14.61 
(SD ± 1.28)
p < 0.001 4.87 
(SD ± 0.36)
2.69 
(SD ± 0.35)
p < 0.001
16.00 8.32 
(SD ± 0.91)
13.44 
(SD ± 1.09)
p = 0.0014 4.77 
(SD ± 0.40)
2.46 
(SD ± 0.37)
p < 0.001
20.00 7.72 
(SD ± 0.69)
14.52 
(SD ± 1.22)
p < 0.001 4.70 
(SD ± 0.34)
2.52 
(SD ± 0.26)
p < 0.001
24.00 7.96 
(SD ± 0.84)
15.30 
(SD ± 1.27)
p < 0.001 5.40 
(SD ± 0.384)
2.67 
(SD ± 0.24)
p < 0.001
04.00 8.66 
(SD ± 1.08)
17.60 
(SD ± 1.59)
p < 0.001 6.18 
(SD ± 0.49)
3.23 
(SD ± 0.26)
p < 0.001
AUC 161.39 
(SD ± 13.40)
298.0 
(SD ± 21.44)
p < 0.001 104.30 
(SD ± 6.90)
54.49 
(SD ± 4.84)
p < 0.001
BGLAP — bone gamma-carboxyglutamate protein, osteocalcin; ICTP — carboxy-terminal telopeptide of type I collagen; AUC — area under curve
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Among patients with hepatitis, we noticed a statisti-
cally significant reduction in total calcium concentration 
in blood (2.20 mmol/L vs. 2.45 mmol/L, p < 0.001) as 
well as the level of inorganic phosphorus (1.06 mmol/L 
vs. 1.33 mmol/L, p < 0.001) compared to the value 
achieved by the control group. We believe that our re-
sults are derived from abnormalities in the metabolism 
of vitamin D and PTH [11, 15].
The common complication described in chronic liver 
diseases, and cirrhosis in particular, is hypogonadism [4, 
26, 39], which also stands as an important risk factor 
for osteoporosis [10, 15, 40, 41]. This disorder manifests 
in laboratory tests as hyperoestrogenism [4, 9, 42–44], 
and a decrease in free testosterone serum level [43, 44]. It 
is true that our study did not have marked levels of sex 
hormones, but by carefully collecting medical history 
and physical examination we were most probably able 
to exclude the influence of gonadal dysfunction among 
study participants. None of the study participants showed 
any signs of alcohol abuse. The consumption of excessive 
amounts of alcohol is a risk factor for osteoporosis, inde-
pendent of hypogonadism and liver dysfunction [26, 45].
In the course of our study, we observed that in pa-
tients with chronic hepatitis daily IGF-I level (3,982.32 
ng/mL vs. 5,167.61 ng/mL, p < 0.001) and IGFBP-3 
level (725.09 ng/mL vs. 944.35 ng/mL, p < 0.001) were 
reduced compared to the control group. Moreover, 
these phenomena were accompanied by increased 
daily secretion of GH in the study group (88.3 ng/mL vs. 
48.04 ng/mL, p < 0.001). This trend has been observed 
by different authors [33, 46, 47]. We noted a positive 
correlation linking BMD and IGF-I and IGFBP-3. 
These observations confirm the importance of 
growth hormone axis function and, consequently, the 
concentrations of IGF-I and IGFBP-3, for bone me-
tabolism [48–50]. Another feature is the appearance of 
a positive relationship between the values of IGF-I and 
BGLAP and negative between IGF-I and ICTP and PTH. 
These relationships indicate a direct effect of liver func-
tion on bone anabolism and catabolism respectively. 
In our opinion, the cause of the increase in the daily 
GH secretion in patients with chronic hepatitis disor-
der feedback was due to impaired production of IGF-I 
in the liver [8, 51]. However, there are reports which 
undermine the aforementioned hypothesis. In animal 
studies, the elimination of hepatic IGF-I synthesis 
caused its level to decrease by 75%, although that action 
did not have any significant influence on the BMD [52, 
53]. Furthermore, some scientists deny the existence of 
a link between IGF-I and BMD in men [54–56]. Papers 
dealing with osteoporosis in liver disease suggest the 
existence of a link between reduced BMI and decreased 
IGF-I and BMD [57-61]. However, our observation did 
not confirm such a relationship.
Our results show a significant reduction in blood 
levels of calcidiol in study subjects compared to the 
control group (712.71 ng/mL vs. 1,535 ng/mL, p < 0.001). 
Vitamin D deficiency may lead to hypocalcaemia, the 
development of secondary hyperparathyroidism, and 
hypophosphatemia [62]. Our research revealed a similar 
tendency, but it should be mentioned that, despite sig-
nificant differences in the concentrations of calcium and 
phosphorus in relation to controls, they stayed within 
the range of reference values for a healthy population. 
Results demonstrating reduced levels of (25(OH)D) 
in the serum of patients with impaired liver function, 
including cirrhosis, have appeared in the past [5, 30, 
63, 64]. However, some reports remain contradictory. 
Diamond et al. [65] and Tsunoka et al. [14] observed 
that the levels of (25(OH)D) and (1,25(OH)2D) show 
significant differences between the groups of patients 
with liver cirrhosis and chronic hepatitis. They point 
to the lower values of these parameters in patients 
with cirrhosis, suggesting a relationship between both 
calcidiol or calcitriol levels and liver efficiency. But there 
are also other opinions: Duarte et al. [66] did not show 
any differences in this area between people with liver 
cirrhosis and a healthy control group. It is worth not-
ing that we found a change in the circadian oscillation 
profile of serum (25(OH)D); in the patient group, it 
showed a much narrower range of diurnal changes in 
addition to an overall lower level compared to healthy 
subjects. We believe this is the premise suggesting 
liver dysfunction in the regulation of vitamin D, far in 
advance of the development of cirrhosis.
Our study showed significantly elevated levels 
of PTH in the hepatitis group members compared to 
the control group (1,201.94 pg/mL vs. 711.73 pg/mL, 
p < 0.001). An increase in PTH levels in patients with 
chronic hepatitis or cirrhosis is usually the result of 
secondary hyperparathyroidism [32, 66, 67]. As previ-
ously mentioned, many authors have suggested that 
the reason for hyperparathyroidism in such patients is 
the decrease of vitamin D level [67, 68]. Previous studies 
have shown that the lowest normal calcidiol levels, at 
which PTH secretion is minimal, is on average 40 ng/mL 
[62, 69]. Among participants in our study, in all the 
samples taken during the day, the concentrations of 
(25(OH)D) levels were below the designated threshold. 
This seems to confirm the hypothesis of hyperpar-
athyroidism being dependent on vitamin D levels in 
patients with chronic active hepatitis. The effect of PTH 
on bone metabolism has been the subject of numerous 
considerations. In the course of hyperparathyroidism, 
the intensification of bone resorption with an increase 
in the number of osteoclasts, severe alteration of bone 
structure and a reduction of BMD has been demon-
strated [25, 70], which is consistent with our results. 
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However, there have also b e e n  reports that short-
pulse increases in PTH have anabolic effects on bone 
mass and increases their mechanical strength [24, 71]. 
There is a suggestion that this effect results from the 
extension of the life of osteoblasts by PTH-dependent 
inhibition of apoptosis [72]. In patients with chronic 
active hepatitis with secondary hyperparathyroidism, 
one would expect an increased bone turnover; how-
ever, this occurs only in about 50% of patients [30, 54, 
73], and in the remainder a dynamic bone disease has 
been described [73].
Our study showed significantly lower serum 
BGLAP concentration in patients with hepatitis (161.39 
ng/L vs. 298 ng/L, p < 0.001), and significantly higher 
levels of ICTP (104.30 µg/L vs. 54.49 µg/L, p < 0.001) 
than in the control group. In addition, we noted a sta-
tistically significant positive correlation joining BMD 
with BGLAP concentration. Our findings are similar to 
those from other authors [74, 75], while Gallego-Rojo 
et al. [30] showed a reduction in the concentration of 
BGLAP only in patients with end-stage liver cirrhosis. 
Previous studies have also shown increased activity of 
bone resorption including ICTP [30, 76]. Most research 
leads us to the hypothesis that the severity of the re-
sorption process is the predominant cause of hepatic 
osteodystrophy.
Conclusions
In our study, we have shown that the impairment 
of liver function in chronic hepatitis due to HBV or 
HCV infection leads in young patients to significant 
disorders of bone metabolism. These changes mani-
fest themselves as a decrease in bone mineral density 
which may reflect in an increased risk of pathological 
bone fractures.
In our research we observed that chronic liver 
inflammation leads to impaired function of the 
calcium-vitamin D-parathyroid hormone axis, 
causes secondary hyperparathyroidism and, conse-
quently, an imbalance in bone turnover processes. 
Furthermore, we have shown that in chronic active 
hepatitis, somatotropin axis adjustment is disturbed; 
this manifests as a decrease in the synthesis of IGF-I 
and IBFBP-3 and, coupled with these, an increase in 
growth hormone secretion.
These observations allow us to conclude that an 
important pathogenetic role underlying hepatic os-
teodystrophy is played by both changes in calciotropic 
hormones and the hormone axis. We believe that there 
may be some significance i n  a change in the metabo-
lism of bone turnover markers — BGLAP and ICTP. 
We believe that the issue we have raised in this 
study requires further research. 
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